Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 464 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Expansion Clear all

Conditions: Neoplasms
Interventions: BI 765179, Ezabenlimab, Pembrolizumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more

Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more

Conditions: Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions: CC-122; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Metastatic and Advanced Solid Tumors
Interventions: NIZ985, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Bethesda, Maryland • St Louis, Missouri • Columbus, Ohio + 4 more

Conditions: Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions: cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing; Drug · Biological · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Follicular, Lymphoma, Peripheral T-Cell, Lymphoma, Hodgkin
Interventions: OT-82 Dose Escalation, OT-82 Dose Expansion; Drug
Lead sponsor: Oncotartis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Birmingham, Alabama • Duarte, California • Miami, Florida + 5 more

Conditions: Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer
Interventions: ECT204 T cells; Biological
Lead sponsor: Eureka Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Duarte, California • Westwood, Kansas • Buffalo, New York + 4 more

Conditions: Metastatic Urothelial Cancer
Interventions: Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 30
States / cities: Tucson, Arizona • San Francisco, California • Littleton, Colorado + 25 more

Conditions: SCLC
Interventions: ZL-1310, Atezolizumab, Carboplatin; Drug
Lead sponsor: Zai Lab (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Duarte, California • New Haven, Connecticut • Sarasota, Florida + 8 more

Conditions: Prostate Cancer
Interventions: DKN-01, Docetaxel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: Exicorilant, Enzalutamide, Placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more

Conditions: Advanced Solid Tumor
Interventions: BT7480, Nivolumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Iowa City, Iowa • New York, New York • Cleveland, Ohio + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
Interventions: Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematologic Malignancies, Hematologic Neoplasms
Interventions: mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus, CD19 Flow Cytometry Assay, CD19 Immunohistochemical Assay, Total Body Irradiation; Biological · Drug · Device + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Non-Small Cell Lung Cancer With MET Mutations
Interventions: Tepotinib; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Sacramento, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more

Conditions: Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood, Childhood Solid Tumor
Interventions: 5 Azacytidine; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 1 Year to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Interventions: FCN-159; Drug
Lead sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • St. Petersburg, Florida + 2 more

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more

Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions: GDC-1971, Osimertinib, Cetuximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
Interventions: [225]-FPI-2059, [111In]-FPI-2058; Drug
Lead sponsor: 3B Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Birmingham, Alabama • Duarte, California • Newport Beach, California + 4 more

Conditions: Myeloproliferative Neoplasms
Interventions: INCA033989, Ruxolitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Duarte, California • Palo Alto, California • Miami, Florida + 9 more

Conditions: Lung Cancer, Adenocarcinoma
Interventions: Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 15
States / cities: Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more

Conditions: Mesothelioma
Interventions: LMB-100, nab-paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma